During my sabbatical research from December 15 2010 to December 14 2011, I spent full time at both labs and clinics in the department of radiation oncology, UT southwestern medical center, Dallas, Texas. At labs of molecular radiation oncology, I worked with the principle investigator and postdoctoral research fellows studying the radio-sensitizing and chemo-sensitizing effect of certain novel drugs targeting DNA-dependent protein kinase (DNA-PK), cyclin-dependent kinase, and EML4-ALK fusion protein in non-small cell lung cancer cell lines. I learned the translation research platform to investigate the therapeutic potential for combined treatment from in vitro cell line study to in vivo animal study. Our work showed that DNA-PK inhibitor is a potent radio-sensitizer in lung cancer cell lines and presents active therapeutic effect in xenograft animal model. It would allow me to build our own platform back to National Taiwan University Hospital for future translational research and development of clinical trial for multi-modality cancer therapy. At clinics of radiation oncology, I attended the stereotactic body radiotherapy (SBRT) training program and followed radiation oncologists in clinical activities. I learned the entire SBRT platform from simulation, treatment planning, quality assurance, and treatment delivery. It would allow me to implement our own SBRT platform in Nation al Taiwan University Hospital to improve our treatment outcome for cancer patients.